Innovation New Jersey
  • Home
  • Our Coalition
    • Contact Us
  • News
  • Resources
    • State Supports
    • Federal Supports
    • Higher Ed Supports
  • Join Us

Innovation News

Everything Innovation. Everything New Jersey.
Follow us and stay connected.

New Report: Advanced manufacturing powering innovative biopharmaceuticals

5/17/2019

0 Comments

 
Washington DC - According to Tim McClung, "The science-based advanced manufacturing infrastructure of the biopharmaceutical industry is critical to fueling the innovation necessary to bring new treatments and cures to patients. With a footprint stretching across the nation, biopharmaceutical manufacturing produces the cutting-edge medicines developed hand-in-glove within the research and development (R&D) ecosystem, providing high-wage STEM jobs, a growing source of exports and sustained investment and productivity gains. To shed light on biopharmaceutical manufacturing in the U.S., PhRMA released a new report on this vital facet of one of America’s most innovative sectors."
The Federal Government’s National Science and Technology Council (NSTC) identified biopharmaceuticals as a priority advanced manufacturing area. In doing so, the Council recognized along with the Brookings Institution and noted economists that U.S. economic growth and prosperity depend upon advanced process engineering and complex manufacturing, which provide the infrastructure for continued innovation. According to NSTC, “Advanced manufacturing—which includes both new manufacturing methods and production of new products enabled by innovation—is an engine of America’s economic power and a pillar of its national security. Advances in manufacturing enable the economy to continuously improve as technologies and innovations increase productivity, enable new products, and create entirely new industries.”
Biopharmaceutical manufacturing stands out as a specialized, complex and highly regulated endeavor with outsized economic contributions. Between 2000-2016, biopharmaceuticals outpaced all other manufacturing sectors in economic output. Biopharmaceutical manufacturing investments in infrastructure were about 50% higher per worker in 2016, compared to the average across all manufacturing. Economic spillovers from these inputs drove construction activity at new and refurbished biopharmaceutical facilities totaling more than $22 billion across 11 states over a 6-year period. Additionally, significant activity in other industries, from packaging and labelling to various ingredient and equipment manufacturers, to high-precision measuring and analytic tool and production components occurred. Among R&D-intensive industries, biopharmaceuticals were the largest exporter of goods in 2017.
The complexity of biopharmaceutical manufacturing reflects the fact that chemistry and biology are the primary processes harnessed in developing and manufacturing medicines, conducted under a regulatory system with strict requirements, high standards and rigorous approvals by the U.S. Food and Drug Administration (FDA). More than 1,100 facilities across 44 states, the District of Columbia and Puerto Rico are currently manufacturing FDA-approved medicines and related products. Beyond this extensive footprint, these facilities are part of a robust innovation ecosystem that brings cutting-edge medicines to patients.
To keep up with as well as advance R&D into new areas, process innovations are as important as product innovations. Biopharmaceutical manufacturers constantly research, develop and adopt new technologies and processes, such as continuous manufacturing, high-volume cell processing, and advanced purification, preservation and distribution modes, all of which are key to manufacturing medicines. Emerging technologies such as new cell and gene therapies are made possible through novel manufacturing processes and capabilities.
Continued innovation throughout the biopharmaceutical life cycle, particularly in the manufacturing process, creates opportunities for new and emerging companies. From 2000-2018, almost $3 billion in venture capital was invested in more than 100 biopharmaceutical startups involved in the development of innovative manufacturing processes or related activities.
While the U.S. is the world’s leader in advanced biopharmaceutical manufacturing, international competitors are trying to close the gap. As the Information Technology and Innovation Foundation observed, “The United States’ lead in the life sciences is being challenged. Other countries have aggressively courted life-sciences companies with lower tax rates…improved intellectual property protections and streamlined approval processes.” Continued U.S. global leadership depends on having the right public policies to support advanced biopharmaceutical manufacturing. Strong intellectual property protections, including patents and data protection; a science-based regulatory system; and coverage and payment policies that recognize the value of medical innovation are critical.
Click here to read the report.
0 Comments



Leave a Reply.

    Do not miss a single innovative moment and sign up for our newsletter!
    Weekly updates


    Categories

    All
    3D Printing
    Academia
    Acquisitions
    Aerospace
    Agriculture
    AIDS
    Algae
    Alumni
    Animals
    Architecture
    Astrophysics
    Autism
    Awards
    Big Data
    Bioethics
    Biofuel
    Biomedical
    BioNJ
    Bioterrorism
    Bit Coins
    Brain Health
    Business
    Camden
    Cancer
    CCollege
    Cellular
    Centenary
    Chemistry
    ChooseNJ
    Climate Change
    Clinical Trials
    Cloud Tech
    Collaboration
    Computing
    Congress
    Coriell
    Council On Innovation
    Crowdfunding
    Cybersecurity
    DARPA
    Defense
    Degree
    Dementia
    Dental Health
    DOC
    DOD
    DOE
    Drew
    Drones
    Drug Creation
    Einstein's Alley
    Electricity
    Energy
    Engineering
    Entrepreneurship
    Environmental
    FAA
    Fairleigh Dickinson
    FDA
    Federal Budget
    Federal Government
    Federal Labs
    Federal Program
    Finance
    Food Science
    Fort Monmouth
    Fuel Cells
    Funding
    Genome
    Geography
    Geology
    Global Competition
    Google
    Governor Christie
    Grant
    Hackensack
    HackensackUMC
    Healthcare
    Health Care
    HHS
    HINJ
    Hospitals
    Immigration
    Incubator
    Infrastructure
    International
    Internet
    Investor
    IoT
    IP
    IT
    Jobs
    Johnson & Johnson
    K-12
    Kean
    Kessler
    Legislation
    Logistics
    Manufacturing
    Medical Devices
    Med School
    Mental Health
    Mentor
    Microorganisms
    Molecular Biology
    Montclair
    NAS
    Neuroscience
    Newark
    New Jersey
    NIFA
    NIH
    NIST
    NJBDA
    NJBIA
    NJ Chemistry Council
    NJCU
    NJDOLWD
    NJEDA
    NJEDge
    NJHF
    NJII
    NJIT
    NJMEP
    NJPAC
    NJPRO
    NJTC
    Nonprofit
    NSF
    OpEd
    Open Data
    OSHE
    OSTP
    Parasite
    Patents
    Paterson
    Patients
    Perth Amboy
    Pharma
    POTUS
    PPPL
    Princeton
    Prosthetics
    Ranking
    Rare Disease
    R&D Council
    Report
    Resiliency
    Rider
    Robotics
    Rowan
    Rutgers
    SBA
    Seton Hall
    Siemens
    Smart Car
    Smart Cities
    Software
    Solar
    Space
    SSTI
    Startup
    State Government
    STEM
    Stevens
    Stockton
    Subatomic
    Supports
    Sustainability
    Taxes
    TCNJ
    Teachers
    Telecom
    Therapy
    Thermodynamics
    Transportation
    Undergraduate
    USEDA
    Verizon
    Video Game
    Virtual Reality
    Water
    WHO
    William Paterson
    Women In STEM
    Workforce Development

Powered by Create your own unique website with customizable templates.